BioCryst Pharmaceuticals
Commercializes oral ORLADEYO and develops injectable navenibart for hereditary angioedema.
$9.82
After-hours close0.00 (0.00%)
At close$9.82(−0.51%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | $0.10 | — | — |
| Aug 2026 | $0.15 | $0.30 | +94.6% |
| May 2026 | $0.06 | −$0.03 | −150.0% |
| Feb 2026 | $0.07 | $1.12 | +1,500.0% |
| Nov 2025 | $0.07 | $0.06 | −14.3% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 2, 2026 | $0.10 | — | — | $165.4M | — | — |
| Aug 5, 2026 | $0.15 | $0.30 | +94.6% | $183.3M | $218.3M | +19.1% |
| May 6, 2026 | $0.06 | −$0.03 | −150.0% | $151.1M | $156.4M | +3.5% |
| Feb 26, 2026 | $0.07 | $1.12 | +1,500.0% | $151.3M | $406.6M | +168.7% |
| Nov 3, 2025 | $0.07 | $0.06 | −14.3% | $151.3M | $159.4M | +5.3% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 4, 2025 | ||||||
| May 5, 2025 | ||||||
| Feb 24, 2025 | ||||||
| Nov 4, 2024 | ||||||
| Aug 5, 2024 | ||||||
| May 6, 2024 | ||||||
| Feb 26, 2024 | ||||||
| Nov 2, 2023 | ||||||
| Aug 3, 2023 | ||||||
| May 3, 2023 | ||||||
| Feb 21, 2023 | ||||||
| Nov 1, 2022 | ||||||
| Aug 4, 2022 | ||||||
| May 5, 2022 | ||||||
| Feb 23, 2022 | ||||||
| Nov 3, 2021 | ||||||
| Aug 5, 2021 | ||||||
| May 6, 2021 | ||||||
| Feb 25, 2021 | ||||||
| Nov 5, 2020 | ||||||
| Aug 6, 2020 | ||||||
| May 6, 2020 | ||||||
| Mar 5, 2020 | ||||||
| Nov 6, 2019 | ||||||
| Aug 6, 2019 | ||||||
| May 8, 2019 | ||||||
| Mar 4, 2019 | ||||||
| Nov 6, 2018 | ||||||
| Aug 7, 2018 | ||||||
| May 8, 2018 | ||||||
| Feb 27, 2018 | ||||||
| Nov 7, 2017 | ||||||
| Aug 7, 2017 | ||||||
| May 4, 2017 | ||||||
| Feb 27, 2017 | ||||||
| Nov 7, 2016 | ||||||
| Aug 4, 2016 | ||||||
| May 5, 2016 | ||||||
| Feb 23, 2016 | ||||||
| Nov 5, 2015 | ||||||
| Aug 7, 2015 | ||||||